HRQOL Analysis of KEYNOTE-522 Supports Pembrolizumab Treatment for Triple-Negative Breast CancerSeptember 12th 2022
Patients with triple-negative breast cancer who received pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores compared with patients who received placebo.
Trastuzumab Deruxtecan Preserves Quality of Life in Patients With HR+, HER2-Low, Metastatic Breast CancerSeptember 12th 2022
A quality-of-life analysis of the pivotal Destiny-Breast04 trial showed that trastuzumab deruxtecan outperformed physician’s choice of treatment in delaying definitive deterioration.
Sacituzumab Govitecan Significantly Prolongs Overall Survival in Patients With HR+/HER2- Metastatic Breast CancerSeptember 10th 2022
Sacituzumab govitecan may represent a promising option for patients with endocrine resistant, hormone receptor–positive/HER2-negative metastatic breast cancer, according to updated findings from the phase 3 TROPiCs-02 study.
Managing AEs With Trastuzumab Emtansine in Breast and Gastric Cancers
Expert perspectives on how to best manage adverse events associated with trastuzumab emtansine while treating patients with breast or gastric cancers.
Role of T-DM1 in Patients With HER2+ Breast and Gastric Cancers
Shared insight on the clinical utility of trastuzumab emtansine in the second- and third-line settings of breast and gastric cancers.
Patient Profile 2: A Patient With HER2+ MBC Treated With T-DM1 who Develops Neuropathy
Shifting focus to a patient profile of HER2+ metastatic breast cancer treated with trastuzumab emtansine, oncology nurse experts review risk of peripheral neuropathy and its management.
Sequencing Therapy in MBC in Second Line and Beyond
Closing out their conversation on the first patient profile, oncology nurse experts consider sequencing therapy following trastuzumab deruxtecan in both breast and GI cancers.
Vaginal Hormone Therapy Is Not Linked to Breast Cancer Recurrence in Post-Menopausal PatientsAugust 29th 2022
An observational study found no association between single-agent vaginal estrogen therapy or menopausal hormone therapy and increased risk of recurrence or mortality in patients with breast cancer.
Selecting Appropriate Patients with MBC for T-DXd and Counseling for AEs
Comprehensive insight to the selection and education of patients for whom ADC therapy is an option in breast or gastric cancers, with regard for pulmonary risk status.
Management of Interstitial Lung Disease Related to T-DXd in Breast or Gastric Cancers
Focused conversation on the occurrence of interstitial lung disease in patients on antibody drug conjugate therapy for breast or gastric cancers.
Prognostic Link Between pCR and Survival Outcomes May Be Key to Personalized Medicine Efforts in Early-Stage TNBCAugust 21st 2022
At the international congress on the Future of Breast Cancer West, Hope S. Rugo highlighted the predictive value of residual cancer burden scoring in ongoing research efforts to tailor triple-negative breast cancer treatments.
Oral Elacestrant Receives Priority Review Status for ER+/HER2– Advanced or Metastatic Breast CancerAugust 18th 2022
Elacestrant, an oral selective estrogen receptor degrader, will undergo evaluation by the FDA for patients with estrogen receptor–positive/HER2-negative advanced or metastatic breast cancer.
Adverse Event Management With T-DXd in Patients With Breast or Gastric Cancers
Contextualizing the use of T-DXd in breast cancer and gastric cancers respectively, panelists highlight optimal management of adverse events in these settings.
Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD
After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.
Podsada Discusses Biomarker Testing and ADC Therapies in Breast CancerAugust 16th 2022
The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.
ESMO Guideline on Liquid Biopsy Address Quality Standards for Clinical ImplementationJuly 27th 2022
In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.
Frontline Ribociclib-Related Quality of Life Favorable to Abemaciclib in HR+/HER2- Advanced Breast CancerJuly 15th 2022
Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.
Early Treatment for Hot-Flashes Is Prognostic of Worse Outcomes for Hormonal Therapy in Patients with ER+ Breast CancerJuly 12th 2022
Patients with breast cancer who experience adjuvant hormone therapy (AHT)-related hot flashes and are treated for hot flashes at the beginning of therapy had worse outcomes than those who did not.